The protection from Pfizer’s COVID-19 vaccine may begin to wane against infection after 2 months, but it still prevents hospitalization and death for at least 6 months, according to two new studies published Wednesday in The New England Journal of Medicine.
The Pfizer COVID-19 vaccine remains 90% effective at reducing a person's risk of hospitalization from the virus six months after it is administered, a new study has found. This is true even in the face of the delta variant as well as if the person has not received a booster shot.
URL copied
More data confirm single dose of Pfizer, AstraZeneca vaccines work
Scientists at Oxford University have released more data that confirm coronavirus vaccines made by Pfizer-BioNTech and AstraZeneca both significantly cut the risk of infection after a single dose. In studies published on Friday, researchers said there was no apparent difference in the vaccines ability to reduce COVID-19 infection rates.
The research has not yet been published in a peer-reviewed journal but is based on data from nose and throat swabs taken from more than 370,000 participants in England and Wales between December and April.
The scientists said that three weeks after people had been given a single dose of either the Pfizer-BioNTech or AstraZeneca vaccine, the rates of all COVID-19 infections fell by 65 per cent. The reduction was bigger after a second dose and the vaccines appeared to protect people against the variant that was first identified in the UK.
Coronavirus: Pfizer vaccine 94% effective, confirms mass real-world study
The research involved about 12 lakh people in Israel. File photo: Syringes prepared for the Pfizer-BioNTech coronavirus vaccine. | Hannibal Hanschke/Reuters
A big real-world test of Pfizer and BioNTech’s coronavirus vaccine has shown that the jab is 94% effective. The results of the study, which involved about 12 lakh people in Israel, were published in the
New England Journal of Medicine on Wednesday
.
The results are very close to the vaccine’s phase 3 clinical trials last year, which found that two doses were 95% effective.
The study estimated the vaccine to be 57% effective against the infection two to three weeks after the first dose and 94% effective a week or longer after the second dose. It involved 6 lakh inoculated people and a similarly-sized control group of unvaccinated participants.
By Lambert Strether of Corrente
As it turns out, I have narrow but deep expertise relevant to the discussion of the New England Journal of Medicine (NEJM) paper on the Pfizer vaccine study, “Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine” (“Safety and Efficacy”), so I thought I’d weigh in, albeit a little late, on the protocols and “exclusion criteria” discussion.
In a past life, several careers ago, I consulted to various large firms, among them medical publishers, on complex document structures; my deliverable would be a formal definition of such structures, plus documentation. For example, and without getting into the weeds on syntax, the structure of all posts at Naked Capitalism includes editorial elements like: a headline (one, required), author (at least one, with an optional bio), and then a long string of running text elements (paragraphs, images, tables, lists, and so on) in any order and any amount greater than one. There are also elements that o